

17w

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 19, 2004.



7/19/04

Kurt A. Summe, Reg. No. 36,023

Date



PATENT

ATTY. DOCKET NO: XANO-42/119

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Heasley	Art Unit:	1614
Serial No.	10/774,803	Examiner:	Unknown
Filed:	February 9, 2004		
Title:	A STABLE PARENTERAL FORMULATION OF LEVOMEPRMAZINE AND A METHOD FOR STABILIZING SAID FORMULATION		

Cincinnati, Ohio

July 19, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


In accordance with the duty of candor and good faith which is imposed by Rule 56 (37 C.F.R. §1.56), the art listed on the attached form PTO-1449 is called to the attention of the U.S. Patent and Trademark Office in connection with the above identified patent application. Copies of the cited references are enclosed. No representation is made that the cited art is the only art or that the cited art represents the best art. The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicant does not believe that any fees are due in connection with this submission as there has yet to be a first Action in this case. However, if such petition is due or any

fees are necessary, the Commissioner may consider this to be a request for such and charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

A handwritten signature in black ink, appearing to read "Kurt A. Summe", is written over a horizontal line.

Kurt A. Summe  
Reg. No. 36,023

2700 Carew Tower  
Cincinnati OH 45202  
(513) 241-2324 Voice  
(513) 421-7269 Facsimile

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/42		SERIAL NO. 10/774,803	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Ralph A. Heasley			
(37 CFR 1.98(b))      (Use several sheets if necessary)							
				FILING DATE February 9, 2004		GROUP 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	A.R	Dahl, Svein G., <u>Pharmacokinetics of methotrimeprazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442					
	A.S	Dahl, Svein, G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40					
	A.T	Dahl, Svein G, et al., <u>Plasma and Erythrocyte Levels of Methotrimeprazine and Two of Its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/42	SERIAL NO. 10/774,803		
<div style="position: relative; height: 100px;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 2px solid black; border-radius: 50%; text-align: center; color: black; font-weight: bold; font-size: 1.2em;"> O I P E JUL 22 2004 PATENT &amp; TRADEMARK OFFICE </div> </div>				INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
				(Use several sheets if necessary)			
				APPLICANT Ralph A. Heasley			
				FILING DATE February 9, 2004	GROUP 1614		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	Gennaro, Alfonso R, Ed., <u>Chapter 45 Oral Solid Dosage Forms</u> , Remington: The Science and Practice of Pharmacy, 20th Edition, 2000, Mack Publishing Co., PA, pp.878-893					
	B.S	Gibson, Ed., <u>Pharmaceutical Preformulation and Formulation</u> , IHS Health Group, Englewood CO, 2001 pp. 331-354, 379-458					
	B.T	Hals, PA et al., <u>Metabolism of levomepromazine in man</u> , European Journal of Drug Metabolism and Pharmacokinetics, 1995; 20:61-71					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/42		SERIAL NO. 10/774,803	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				APPLICANT Ralph A. Heasley			
				FILING DATE February 9, 2004		GROUP 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	C.A.	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.B.						
	C.C.						
	C.D.						
	C.E.						
	C.F.						
	C.G.						
	C.H.						
	C.I.						
	C.J.						
	C.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L.						
	C.M.						
	C.N.						
	C.O.						
	C.P.						
	C.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	C.R.	Sztruhar, I et al., <u>Liquid chromatographic resolution of the enantiomers of psychotropic drug levomepromazine (methotrimeprazine) with beta-cyclodextrin-bonded chiral stationary phase</u> , Journal of Pharmaceutical & Biomedical Analyses, 1993; 3:263-266					
	C.S.						
	C.T.						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							